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Abstract
Background: Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, end-stage liver disease and
hepatocellular carcinoma (HCC) worldwide. In Europe, people who inject drugs (PWID) represent the majority of
HCV infections, but are often excluded from treatment. The aim of this study was to report on national HCV
strategies, action plans and guidelines in European countries that include HCV treatment for the general population
as well as for PWID. Data on access to direct-acting antivirals (DAAs) were also collected.
Methods: In 2016, 38 non-governmental organisations, universities and public health institutions that work with
PWID in 34 European countries were invited to complete a 16-item online survey about current national HCV
treatment policies and guidelines. Data from 2016 were compared to those from 2013 for 33 European countries,
and time trends are presented. Differences in the data were analysed. Data from 2016 on general access to DAAs in
PWID are presented separately.
Results: The response rate was 100%. Fourteen countries (42%) reported having a national HCV strategy covering
HCV treatment; 12 of these addressed HCV treatment for PWID. Respondents from ten countries (29%) reported
having a national HCV action plan. PWID were specifically included in seven of them. Twenty-nine countries (85%)
reported having national HCV treatment guidelines. PWID were specifically included in 23 (79%) of them. Compared
to 2013, respondents reported that an additional seven countries (25%) had national strategies, an additional eight
countries (29%) had action plans and an additional six countries (19%) had HCV treatment guidelines. However,
PWID were not included in two, four and six of those countries, respectively. DAAs were reported to be available in
91% of the study countries, with restrictions reported in 71% of them.
Conclusion: Respondents reported that fewer than half of the European countries in this study had a national HCV
strategy and/or action plan, with even fewer including PWID. However, when compared to 2013, the number of
such countries had slightly increased. Although PWID are often addressed in clinical guidelines, strategic action is
needed to increase access to HCV treatment for this group and the situation should be regularly monitored.
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Background
Injecting drug use is reported to be the main route of
hepatitis C virus (HCV) transmission in Europe. It
accounted for 78% of all new HCV infections with a
known transmission route in 2015 [1]. Among an esti-
mated 4.5 million persons who inject drugs (PWID) in
the region of WHO Europe, the total number of HCV
seropositive PWID is estimated to be 2.7 million (60%)
and an estimated 2 million PWID are chronically in-
fected with HCV.
HCV seroprevalence rates vary considerably among
European Union (EU) member states. In PWID, esti-
mates range between 14% reported in the Czech Repub-
lic to 84% reported in Portugal. Five out of the 13
countries with national data reported a rate of over 50%
in 2015 [2–5].
Chronic HCV infection causes progressive liver damage,
and cirrhosis develops in approximately 16% of infected
individuals approximately 20–30 years after infection [6].
Persons with cirrhosis are at increased risk of developing
end-stage liver disease and hepatocellular carcinoma
(HCC). As PWID with chronic HCV infections age, the
existing HCV-related morbidity and mortality burden on
health systems is likely to increase [7, 8].
The introduction of highly effective, interferon-free
direct-acting antiviral (DAA) regimens has revolutio-
nised HCV treatment [9]. However, the WHO Global
hepatitis report estimated that worldwide, in 2015, only
20% of HCV-infected people had been diagnosed and
only 7% of those diagnosed had initiated treatment [10].
Significant variation in availability and access to treat-
ment still exists between and within European countries
[10]. Treatment rates in European PWID diagnosed with
HCV have been estimated to be between 10% and 30%,
with wide variation reported across settings [5, 11, 12].
There are several described barriers to HCV treatment,
particularly for PWID, despite several studies reporting
high therapy adherence rates and low rates of reinfection
[13]. Additionally, dynamic modelling suggests that HCV
treatment for PWID can reduce the prevalence and inci-
dence of chronic HCV infection [14]. Modelling studies on
“treatment as prevention” have shown that achieving high
DAA treatment coverage among chronically HCV-infected
PWID has considerable public health value [15]. Further-
more, economic evaluations suggest that treating PWID
with DAA regimens is cost-effective in high-income set-
tings [13, 16–18].
In recent years, the guidelines of the European Associ-
ation for the Study of the Liver (EASL), World Health
Organization (WHO) and other expert associations have
recommended that PWID be considered for HCV treat-
ment [9, 19]. These recommendations call for PWID to be
treated without delay, as untreated HCV patients have the
potential to further transmit HCV. Despite these and
other recommendations [20], low HCV treatment uptake
levels are still observed among PWID [11, 12].
Resource capacities in European countries differ sub-
stantially, as do health priorities, and levels of access to
HCV treatment [21]. In most European countries, treat-
ment is prioritised based on fibrosis stage and/or presence
of extra-hepatic manifestations of infection, such as mem-
branoproliferative glomerulonephritis or peripheral poly-
neuropathy, or concomitant HIV infection. The first
WHO Global Health Sector Strategy on Viral Hepatitis
(published in June 2016) recommends that strategies, ac-
tion plans and guidelines for HCV treatment be developed
in each country according to each country’s individual epi-
demiology, population affected, organisation of the health-
care and community system and resource capacities,
which should be aligned with existing plans [22].
In light of the apparent incongruences between these
WHO recommendations and 2013 data collected from 33
European countries showing relatively few national strat-
egies, action plans or clinical guidelines for the treatment
of HCV, particularly for PWID [23], this study aimed to
report changes over time. Special attention was paid to
the inclusion of PWID in national strategies, action plans
and clinical guidelines on HCV treatment. Access to
DAAs in different European countries for the general
population, and PWID in particular, was also studied.
Methods
A 16-item, an electronic questionnaire was designed and
set up at the Clinic for Infectious Diseases and Febrile
Illnesses at the University Medical Centre in Ljubljana,
Slovenia. This questionnaire was sent via e-mail to re-
spondents from the same 33 European countries as in
the 2013 study [23], as well as to respondents in
Ukraine. Scotland was categorised separately from the
rest of the UK because of the Scottish National Health-
care System’s unique approach to HCV management.
The data from the UK therefore excludes all data from
Scotland. Informants were drawn from a database of
contacts provided by the Hepatitis C Initiative from the
Correlation Network. Responses were collected from
September to December 2016.
The questionnaire included questions relating to
national-level HCV management and HCV treatment
access. In the first part, questions on the existence of a
national strategy, action plan and guidelines for treat-
ment of HCV were provided followed by questions on
whether these three options include activities regarding
PWID and precise questions on the existence of separate
HCV treatment guidelines for PWID, applicable to those
on opioid substitution therapy (OST) and active injec-
tors. In the second part, questions on the availability of
DAAs and official policy restrictions for their use were
given. “Yes” or “no” were the only possible responses to
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these questions. Respondents were asked to provide refer-
ences for national guidelines on HCV treatment and had
the option of adding comments to clarify their answers.
The survey also requested the names, organisational affili-
ations and countries of respondents. The questionnaire
was administered in English, as all respondents had previ-
ously reported fluency in the English language.
This study used the same definition of PWID used in
the 2013 baseline study [23]: PWID were either people
who had been “actively” injecting drugs, referring to
those who had used drugs in the past 6 months, or
people who were former injectors. Those who were still
active non-injection drug users and/or were on OST
were considered to be former injectors. This definition
was taken from recommendations published by the
International Network on Hepatitis in Substance Users
(INHSU) in 2013 [24].
As in the study from 2013, the definitions for the terms
national strategy, action plan and clinical guidelines were
not specified. The respondents were expected to under-
stand them similarly, since they are commonly used in the
national health sector. No checking regarding the proper
use of these terms among the respondents was planned.
However, in case of poor understanding or misunder-
standing of the questionnaire, the possibility for clarifica-
tion was provided by the Correlation Network, either via
email or phone.
Data were collected by the Hepatitis C Initiative from
the Correlation Network and then reviewed and ana-
lysed by the authors. The results from the first section of
the questionnaire were compared to the results from the
2013 study. A positive trend for a particular question
was defined as a respondent responding “no” to a ques-
tion in 2013 and “yes” to the same question in 2016. A
negative trend for a particular question was defined as a
respondent answering “yes” to a question in 2013 and
“no” to the same question in 2016. In the latter, the re-
spondent was asked to recheck the response for 2016. If,
after rechecking, the respondent confirmed the response
for 2016 to be correct, that country would have been ex-
cluded from further analysis for that particular question.
Results
All 34 of the invited European countries participated in the
survey. In four countries, surveys were completed by two
different respondents in each country (Czech Republic,
Finland, Greece and Slovenia). In these countries, respon-
dents provided congruent answers regarding their respective
national strategies, action plans and guidelines. However,
their answers to the second section of the questionnaire dif-
fered. When asked for clarification of the discrepancies, con-
firmation was received only from one Greek and one
Slovenian respondent. The responses from these two latter
respondents were included in the study.
Respondents had differing affiliations: most of them
(27/38, 71%) represented non-governmental organiza-
tions (NGOs), six (16%) were based in university hospi-
tals, four (10%) at public health institutions and one
(3%) came from a private clinic that provided medical
care to PWID. The ratio of various affiliations of the re-
spondents was comparable to the study from 2013,
representing 67%, 18%, 12%, and 3%, respectively.
National strategy, action plan and clinical guidelines for
treatment of HCV infection
Fourteen of 34 countries (42%) reported having a na-
tional strategy for the treatment of HCV (Fig. 1). PWID
were not included in only two of these countries, and
one provided no answer regarding PWID. Ten countries
(29%) reported having a national action plan for the
treatment of patients with HCV infection (Fig. 1). PWID
were included in seven of these countries.
The majority of the countries (29/34, 85%) reported
having national guidelines for the treatment of HCV in-
fection. PWID were reported to be included in all but
four of these. Six countries (18%) reported that they had
separate guidelines for treating PWID with HCV infec-
tion; six countries reported that there were separate
guidelines for PWID concurrently being treated with
OST. Two countries reported that separate treatment
guidelines were applicable for PWID on OST whereas ac-
tive drug users were not included in the treatment guide-
lines. Active drug users were reported to have separate
treatment guidelines in four countries. Respondents from
17 countries provided no response to the question of
treatment guidelines for active drug users (Table 1).
Comparison of the results from 2013 and 2016
With the exception of Ukraine, which was excluded
from the comparison, all of the other 33 countries were
included in both the 2013 and 2016 studies. The various
affiliations of the respondents were approximately the
same between the two studies.
Comparing the two study years, a positive trend in a
response to at least one question was observed in 16
countries (48%). A negative trend was observed in 11 re-
sponses coming from a total of eight countries; no
changes in responses were detected from the remaining
countries (Table 1) [25–65]. After reconfirmation of the
responses for 2016, the responses with negative trends
on the existence of a national strategy, action plan or
clinical guideline coming from five, five and two coun-
tries, respectively, were excluded from further analysis.
A positive trend in responses on the existence of a na-
tional strategy, action plan or clinical guideline was re-
ported from seven, eight and six countries, respectively.
These represent 25%, 29% and 19% increases, respect-
ively (Fig. 2). Although positive trends were observed,
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PWID were still reported to be excluded from the na-
tional strategies, action plans and clinical guidelines in
2/7, 4/8 and 4/6 countries, respectively (Fig. 2).
Availability and accessibility of direct-acting antivirals
With the exception of three responding countries, DAAs
for HCV were available in the remaining countries (31/34,
91.2%) (Additional file 1).
Most countries with available DAAs reported having
official policy restrictions for their use (22/31, 71%)
(Additional file 1). Only four countries reported that
they had no restrictions on DAA prescribing. One par-
ticipant from one country did not respond.
In two countries (2/22, 9%), DAAs were used for cir-
rhotic patients only (fibrosis stage 4). In five countries
(5/22, 23%), DAAs were prescribed only to treat patients
with advanced fibrosis (stages > 3). In 12 countries (12/22,
55%), patients were retreated only if they were at the sec-
ond stage of liver fibrosis or higher. Respondents from
three countries (3/22, 14%) did not declare any limitations
based on the stage of liver fibrosis. All, but one country,
with available DAAs (31) also prescribed for various sub-
groups of PWID. Among the remaining 30 countries,
treatment with DAAs was available for PWID on OST
whereas active drug users reported being treated with
DAAs in 24 countries (77%). In seven countries (23%),
DAA treatment was limited only to PWID on OST. In
Estonia, PWID were reported to be allowed to receive
DAAs; however, they had to belong to one of the sug-
gested PWID subgroups.
In most countries (25/31, 80%), DAAs were reported
to be prescribed in accordance with official policies. This
was not the case in three countries. Three additional
countries did not answer this question. In 13 countries,
only clinicians were reported to be able to make the final
decision to treat with DAAs (13/31, 42%). In two coun-
tries (2/31, 7%), the decision to treat with DAAs was re-
ported to be made by both clinicians and health insurance
companies. In six countries (19%), the decisions were re-
ported to be made by both clinicians and special medical
commissions. In three countries (10%), the decisions were
reported to be made only by special medical commissions.
In four countries (13%), the decisions were reported to be
made by all stakeholders: clinicians, special medical com-
missions and health insurance companies. In one country,
the decision was reported to be made by other means
apart from the three suggested options.
In 13 of the 34 countries surveyed (38%), HCV-infected
PWID were reported to be treated at infectious disease
clinics. In nine countries (9/34, 27 %), HCV was reported
to be treated at both gastroenterology and infectious dis-
ease clinics, whereas in seven countries (7/34, 21%), HCV
treatment for PWID was reported to be offered also in
drug addiction centres. In two other countries (2/34, 6%),
all of the previously mentioned settings, as well as general
practitioners, were reported to treat PWID. In eight coun-
tries (8/34, 24%), HCV in PWID was reported to be
Fig. 1 Reported presence of the national strategies, action plans and clinical guidelines for the treatment of hepatitis C from 34 European
countries in 2016. #Scotland was treated separately from the UK. The countries in gray participated in the study in 2013. The countries in gray and
white participated in the study in 2016. ##The colored circles represent the existence of the national strategies (green), action plans (yellow) and
clinical guidelines (red) in a particular country. ###People who inject drugs were not included in the national strategy in Belgium and Portugal.
####People who inject drugs were not included in the action plan in Belgium, Portugal and Romania. #####People who inject drugs were not
included in the clinical guidelines for the treatment of hepatitis C in Albania, Lithuania, Spain and Sweden















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Maticic et al. Harm Reduction Journal           (2019) 16:32 Page 8 of 13
treated also by other types of physicians. With the excep-
tion of Ukraine, all countries with available DAAs (30/31,
97%) reported that treatment for HCV is reimbursed
(Additional file 1).
Discussion
This study examined the current policies and guidelines
that address hepatitis C treatment for PWID in 34 Euro-
pean countries. The WHO Global Health Sector Strategy
on Viral Hepatitis sets out strategic directions and prior-
ity actions based on the best available scientific evidence
[22]. Therefore, it serves as an essential tool for coun-
tries to use when developing more focused responses to
their viral hepatitis epidemics. By comparing the 2016
survey results with those from 2013, we evaluated the
influences that the WHO and EASL treatment guide-
lines have had on European countries in terms of their
HCV management efforts [9, 66]. As such, this is the
first pan-European study to evaluate the real-life dynam-
ics of these international treatment recommendations.
Highly effective DAAs promise significant individual
and public health benefits. In the context of this new
treatment, the WHO Global Health Sector Strategy on
Viral Hepatitis calls for the elimination of viral hepatitis
as a public health threat by 2030 [22]. To achieve this
goal, an increased capacity for HCV treatment is critical
in most European countries. A modelling study that in-
cluded 28 EU countries showed that to achieve the
WHO targets, unrestricted treatment needs to increase
from 150 000 patients in 2015 to 187 000 patients in
2025 [67]. This must be carried out in addition to scal-
ing up screening capacities [68]. Several studies have
found that there are barriers to the scale-up of HCV
treatment in high-risk populations, particularly in PWID
[69]. Because PWID are the major drivers of the HCV
epidemic in the European region, responding to this
situation with effective measures is essential for reaching
the hepatitis C elimination goal set out by WHO.
This study found widespread variation in terms of
HCV treatment in general and among PWID in particu-
lar. At the time of data collection, only 42% of the 34
European study countries reported having a national
hepatitis strategy and 29% reported having a national ac-
tion plan. When comparing these results with the 2016
HEP-Core Report, a patient-led viral hepatitis policy
monitoring tool comprising of 27 European countries, a
discrepancy was noted in reporting the existence of na-
tional hepatitis strategies in five countries that were in-
cluded in both studies [21]. However, neither the
Hep-CORE Study nor our study defines the terms na-
tional strategy or national action plan. Further, the
WHO Global Health Sector Strategy does not provide a
precise definition of these terms, but rather extensively
present strategic directions for priority actions by coun-
tries, which most probably guided the respondents of
our study.
Comparing the results obtained in 2013 and 2016, it
was observed that 25% more countries reported having
national strategies in 2016 than in 2013 and that 29%
more countries reported having national action plans in
2016 than in 2013. Some positive trends have also been
observed in recognizing PWID as a group of individuals
where strategic action is needed to increase HCV treat-
ment; however, these data were far from satisfactory with
regard to the WHO Global Health Sector Strategy on
Viral Hepatitis [22].
The results from our 2016 survey showed that most
European countries have national guidelines for the
treatment of HCV, with the treatment of PWID included
in their respective guidelines. Four countries even re-
ported having separate treatment guidelines for PWID.
When comparing these data to the data from the 2016
HEP-Core Report, almost identical results were noted
[21]. However, when comparing the results from 2013 to
those from 2016, only a 19% increase in the number of
countries with treatment guidelines was observed. The
Fig. 2 The comparison of results from 2013 and 2016 surveys on the reported presence of national strategies, action plans and clinical guidelines
for the treatment of hepatitis C in 33 European countries with regard to people who inject drugs. PWID people who inject drugs
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treatment guidelines of six of the28 countries with such
guidelines still do not include PWID.
Despite DAAs being reported to be available in 91% of
the European countries studied, restrictions on their use
were reported in a majority of them. Restrictions were
based on a variety of factors. The most common reason
for a patient to be denied DAAs was reported to be his
or her stage of liver fibrosis, and the second most com-
mon reason was concurrent injecting drug use. The
Hep-CORE study also found that these were the most
common reasons for European countries to restrict
DAA treatment. Other reasons for DAA restriction in
the Hep-CORE study included abstinence from injecting
drugs for a specific period of time, alcohol use, lack of
Ostia case of past or present drug use and others. Ac-
cording to our survey, all countries except one (97%) re-
ported DAAs to be available for PWID on substitution
therapy, but were less commonly allowed for actively
injecting PWID.
Of interest, the review of the official documentation
on reimbursement of HCV treatment in 35 European
countries and jurisdictions was performed between 18
November 2016 and 1 August 2017 by a group of na-
tional experts [70]. It showed that 16 (46%) countries
and jurisdictions required patients to have fibrosis at
stage F2 or higher; 29 (83%) had no listed restrictions
based on drug or alcohol use; 33 (94%) required a spe-
cialist prescriber; and 34 (97%) had no additional restric-
tions for people co-infected with HIV and HCV. These
findings were slightly discrepant with the results of this
study, as well as with the results of the Hep-CORE study
[21]. In these two studies, respondents were NGO repre-
sentatives, and the discrepancy points to an important gap
between knowledge among a key stakeholder group (pa-
tient associations and non-governmental service pro-
viders), and what official national documents state and
possibly implementation gaps. Future research may wish
to directly assess the knowledge among key stakeholders
of national policies and their opinions of these, including
their operationalisation, rather than asking this group to
report on national policies and their contents.
DAAs were reported to be prescribed predominantly
in accordance with official policies. Infectious disease or
gastroenterology and hepatology specialists almost ex-
clusively prescribed DAAs within hospital settings. The
implication of these findings is that even with the pres-
ence of a strategy to overcome barriers that prevent
PWID to access HCV treatment, many countries may be
failing to implement it [71–73]. While barriers for PWID
to access HCV treatment have been reported in a num-
ber of studies [74, 75], treatment outside medical set-
tings can be as effective as a treatment in hospitals,
especially for marginalised populations such as PWID,
and help overcome linkage-to-care challenges [76].
The findings of this study may provide some tangible
context to the WHO Global Health Sector Strategy,
which calls for health systems to deliver hepatitis treat-
ment to different populations and settings, reinforce
strategic linkages between various health services, ensure
the quality of services and actively engage communities
[22]. Therefore, the roles and responsibilities at every
level of the health system need to be defined with re-
spect to their delivery of hepatitis treatment—from
community-based and primary health services to tertiary
referral centres. There is evidence that HCV treatment
can be successful in PWID and efforts to improve the
generally low uptake of HCV treatment among PWID
must consider the willingness of health systems and in-
dividual health providers to administer HCV treatment
to members of this population [11, 77–79].
The most important limitation of this study is the in-
volvement of only stakeholders selected from the Correl-
ation Network’s Hepatitis C Initiative database. Most were
representatives of NGOs but were not necessarily familiar
with their respective government’s HCV policy. The valid-
ity of the answers provided was not cross-referenced with
current, official policy, so there may be inaccuracies in re-
spondents’ answers. However, by comparing our results to
those of the Hep-CORE study, we emphasise the import-
ance of combining data collected from various stake-
holders. Further research should explore the perspectives
of various civil society stakeholders, experts and govern-
ment officials in Europe on current policy and practice.
Conclusions
This is the first study to present trends in the develop-
ment of national action plans, strategies and guidelines
on HCV treatment for PWID in Europe. Between 2013
and 2016, there was a positive trend in recognising
PWID as a group of individuals for whom strategic ac-
tion is needed to increase access to and availability of
HCV treatment. In the majority of European countries,
DAAs were reported to be available; however, restric-
tions on their use were reported in almost all of them, of
which the most common were fibrosis stage, and current
and/or previous injecting drug use.
In order to reduce the HCV-related disease burden
among PWID, a radical change in the HCV response is
needed in many of the European countries investigated
in this study. National strategies, action plans and guide-
lines that specifically address recommendations for
treating PWID with HCV need to be further developed
and adopted. Involving all stakeholders, including rele-
vant NGOs, in the monitoring and reporting of national
responses would be a significant step forward towards
the elimination of HCV as a public health threat, as set
out in the WHO Global Health Sector Strategy on
Hepatitis, 2016–2021.
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Additional file 1: Study results on access to hepatitis C treatment with
direct-acting antivirals in 2016 from 34 European countries. (DOCX 21 kb)
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